Ischemix announced positive data from a Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative cardiac ischemia-reperfusion injury. The trial achieved its primary endpoint of safety with CMX-2043 demonstrating a favorable safety profile at all doses, consistent with the Phase 1 data. CMX-2043 demonstrated positive trends in all secondary efficacy endpoints of myocardial injury defined by the post-procedural rise in the cardiac biomarkers CK-MB and Troponin T, and achieved statistically significant benefits in a key endpoint measure of cardiac protection. The Prospective, Randomized (3:1), Comparative, Blinded, Placebo-Controlled, Three Different Intravenous Dose, Phase 2a Study of the Safety and Efficacy of CMX-2043 in Subjects Undergoing PCI and Peri-Operative Reperfusion Treatment (SUPPORT-1) enrolled patients at investigational sites throughout the United States and India.
